Shares of Vertex Pharmaceuticals (VRTX) were climbing by 22.86% to $161.19 in after hours trading on Tuesday afternoon, after the bio therapeutic drug company said it has seen positive data from its Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis.

Cystic fibrosis is an inherited disorder that causes damage to the lungs, digestive system, and other organs of the body, Moya Clinic explains. The disease impacts the cells that produce mucus, sweat, and digestive fluids.

"These safety and efficacy data are clear and compelling, indicating significant potential benefit for people with CF from each of these three different triple combination regimens," Vertex Chief Medical Officer Jeffrey Chodakewitz said.

Vertex is going to continue to evaluate the data and decide on which regimens it will take forward into key programs in the first half of next year.

More from Stocks

3 Software Stocks Now Available at a Discount

3 Software Stocks Now Available at a Discount

EOG Resources Is the Stock to Own in This Crude Oil Rally

EOG Resources Is the Stock to Own in This Crude Oil Rally

Why Big Mergers Are Still Happening Even With Stocks at Record Highs

Why Big Mergers Are Still Happening Even With Stocks at Record Highs

An Alibaba Trade Setup Off Weekly Support

An Alibaba Trade Setup Off Weekly Support

Accenture Has Nearly Reached a Point & Figure Target; Raise Sell Stops

Accenture Has Nearly Reached a Point & Figure Target; Raise Sell Stops